Molecular, genetic and neuroimaging mechanisms of relapse recovery in multiple sclerosis: exploring the role of brain-derived neurotrophic factor - LIONHEARTED (moLecular, genetIc and neurOimagiNg mecHanisms of rElApse recovery in multiple sclerosis: exploRing The role of brain-derivED neurotrophic factor)

Klinik für Neurologie, Universitätsklinikum Frankfurt0 sites200 target enrollmentJanuary 3, 2023

Overview

No summary available.

Registry

who.int

Start Date

January 3, 2023

End Date

TBD

Last Updated

last year

Study Type

Observational

Sex

All

Sponsor

Klinik für Neurologie, Universitätsklinikum Frankfurt

•Inclusion criteria for the adult MS group: ability to give informed consent; age 18\-60 years; relapsing MS; disease duration \= 10 years; last relapse and IVMP/plasmapheresis/immunoadsorption \> 30 days ago; no DMT or stable on DMT for the last \= 6 months.
•Inclusion criteria for the pediatric MS group: parents’ ability to give informed consent; age 6\-17 years; relapsing MS; disease duration \= 15 years; last relapse and IVMP/plasmapheresis/immunoadsorption \> 30 days ago; no DMT or stable on DMT for the last 6 months.

•Exclusion criteria for the adult MS group: no ability to give informed consent, age \< 18 or \> 60 years; progressive MS with no relapses; disease duration \> 10 years; last relapse and IVMP/plasmapheresis/immunoadsorption \= 30 days ago; DMT initiation or not stable on DMT in the last \< 6 months.
•Exclusion criteria for the pediatric MS group will be: missing ability of the parents to give informed consent, age \< 6 or \> 18 years; progressive MS with no relapses; disease duration \> 15 years; last relapse and IVMP/plasmapheresis/immunoadsorption \= 30 days ago; DMT initiation or not stable on DMT in the last 6 months.